{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:21:26Z","timestamp":1762867286763,"version":"3.41.2"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We evaluated trends in\n            <jats:named-content content-type=\"genus-species\">Streptococcus pneumoniae<\/jats:named-content>\n            antimicrobial susceptibility in United States hospitals in the 2010 to 2016 period. A total of 8,768 clinical isolates from 47 medical centers were tested for susceptibility by broth microdilution methods. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) rates decreased from 25.7% and 12.4%, respectively, in 2010 to 17.7% and 3.6%, respectively, in 2016. The susceptibilities to most comparator antimicrobial agents increased, whereas the susceptibilities to ceftaroline, levofloxacin, linezolid, and tigecycline remained stable. Ceftaroline retained potent activity against\n            <jats:named-content content-type=\"genus-species\">S. pneumoniae<\/jats:named-content>\n            (&gt;99.9%) with no marked variations.\n          <\/jats:p>","DOI":"10.1128\/aac.01555-17","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T17:10:13Z","timestamp":1511197813000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["<i>In Vitro<\/i>\n            Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016)"],"prefix":"10.1128","volume":"62","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"University of Iowa, Iowa City, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard R.","family":"Duncan","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02453-16"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.03.2130"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv107"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.08.024"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02976-14"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis561"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03344-14"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.05.020"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"iii45","DOI":"10.1093\/jac\/dkr098","article-title":"Review of ceftaroline fosamil microbiology: integrated FOCUS studies","volume":"66","author":"Critchley IA","year":"2011","unstructured":"Critchley IA, Eckburg PB, Jandourek A, Biek D, Friedland HD, Thye DA. 2011. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J Antimicrob Chemother 66 Suppl 3:iii45\u2013iii51.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0075-6"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis563"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02557-13"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2016.0258"},{"key":"e_1_3_2_15_2","volume-title":"Teflaro, package insert","author":"Allergan plc","year":"2016","unstructured":"Allergan plc. 2016. Teflaro, package insert. Allergan plc, Dublin, Ireland. http:\/\/www.allergan.com\/assets\/pdf\/teflaro_pi."},{"key":"e_1_3_2_16_2","volume-title":"M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201410th ed. M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_2_17_2","volume-title":"M100-S26","author":"Clinical and Laboratory Standards Institute","year":"2016","unstructured":"Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26th informational supplement. M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_18_2","volume-title":"Tygacil, package insert","author":"Wyeth Pharmaceuticals","year":"2014","unstructured":"Wyeth Pharmaceuticals. 2014. Tygacil, package insert. Wyeth Pharmaceuticals, Dallas, TX. www.tygacil.com. Accessed 25 January 2016."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01555-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01555-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:14:31Z","timestamp":1645478071000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01555-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1128\/AAC.01555-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01555-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"2017-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01555-17"}}